本研究评估了交界性卵巢肿瘤 (BOT) 幸存者与仅接受手术治疗的早期卵巢癌幸存者以及匹配的无癌人群的健康相关生活质量 (HRQo)。BOT 和卵巢癌的幸存者受邀参加两项荷兰横断面、基于人群的研究。仅接受手术治疗的肿瘤 I 期卵巢癌幸存者也被纳入其中。来自无癌症人群的随机样本与 BOT 幸存者样本的性别、年龄和教育程度相匹配。 EORTC QLQ-C30（3.0 版）和 EORTC QLQ-OV28 由研究 1 和 2 中的无癌人群以及 BOT 和卵巢癌幸存者完成。医院焦虑和抑郁量表 (HADS) 仅由研究 2 中的无癌人群以及 BOT 和卵巢癌幸存者完成。研究 1 中的无癌人群以及 BOT 和卵巢癌幸存者。使用线性回归分析和关于临床重要性的效应大小，将 BOT 幸存者与早期卵巢癌幸存者和一般人群进行比较。83 BOT (42%), 88早期卵巢癌幸存者 (52%) 和普通人群中的 82 名女性被纳入其中。在大多数 HRQoL 领域，BOT 幸存者与早期卵巢癌幸存者和无癌人群没有显着差异，除了 BOT 幸存者报告的失眠症明显少于早期卵巢癌幸存者，并且比无癌人群有更多呼吸困难。一般而言，BOT 幸存者的 HRQoL 介于早期卵巢癌幸存者和无癌人群的 HRQoL 之间，但各组之间的临床效应大小大多微不足道。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

This study assessed the health-related quality of life (HRQo) of women surviving a borderline ovarian tumor (BOT) in comparison with early-stage ovarian cancer survivors treated surgically alone and with a matched cancer-free population.Survivors of BOT and ovarian cancer were invited in two Dutch cross-sectional, population-based studies. Ovarian cancer survivors with tumor stage I who were treated surgically only were included. A random sample from the cancer-free population was matched on sex, age and education to the sample of BOT survivors. The EORTC QLQ-C30 (version 3.0) and the EORTC QLQ-OV28 were completed by the cancer-free population and the BOT and ovarian cancer survivors in study 1 and 2. The Hospital Anxiety and Depression Scale (HADS) was only completed by the cancer-free population and the survivors of BOT and ovarian cancer in study 1. BOT survivors were compared to early-stage ovarian cancer survivors and the general population using linear regression analyses and effect sizes regarding clinical importance.83 BOT (42%), 88 early-stage ovarian cancer survivors (52%), and 82 women from the general population were included. In most HRQoL domains, BOT survivors were not significantly different from early-stage ovarian cancer survivors and the cancer-free population, except that BOT survivors reported significantly less insomnia than early-stage ovarian cancer survivors and more dyspnea than the cancer-free population (small clinical difference).In general, BOT survivors' HRQoL lies between the HRQoL of early-stage ovarian cancer survivors and of the cancer-free population, but clinical effect sizes between the groups were mostly only trivial.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.